The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2017
Filed:
Aug. 06, 2015
Applicant:
Glaxo Group Limited, Brentford, Middlesex, GB;
Inventors:
Véronique Birault, Stevenage, GB;
Amanda Jennifer Campbell, Stevenage, GB;
Stephen Harrison, Stevenage, GB;
Joelle Le, Stevenage, GB;
Assignee:
Glaxo Group Limited, , GB;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 215/02 (2006.01); C07D 215/58 (2006.01); C07C 311/44 (2006.01); C07C 311/21 (2006.01); C07C 311/29 (2006.01); C07D 213/30 (2006.01); C07D 213/38 (2006.01); C07D 213/61 (2006.01); C07D 213/65 (2006.01); C07D 213/68 (2006.01); C07D 213/75 (2006.01); C07D 233/22 (2006.01); C07D 239/28 (2006.01); C07D 249/08 (2006.01); C07D 257/04 (2006.01); C07D 261/08 (2006.01); C07D 213/42 (2006.01); C07D 231/12 (2006.01); C07D 233/64 (2006.01); C07D 239/26 (2006.01); C07D 239/34 (2006.01); C07D 213/73 (2006.01);
U.S. Cl.
CPC ...
C07C 311/44 (2013.01); C07C 311/21 (2013.01); C07C 311/29 (2013.01); C07D 213/30 (2013.01); C07D 213/38 (2013.01); C07D 213/42 (2013.01); C07D 213/61 (2013.01); C07D 213/65 (2013.01); C07D 213/68 (2013.01); C07D 213/73 (2013.01); C07D 213/75 (2013.01); C07D 231/12 (2013.01); C07D 233/22 (2013.01); C07D 233/64 (2013.01); C07D 239/26 (2013.01); C07D 239/28 (2013.01); C07D 239/34 (2013.01); C07D 249/08 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); C07C 2101/16 (2013.01);
Abstract
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.